Duration of humoral immunity and cross-neutralizing activity against the Alpha, Beta, and Delta variants after wild-type SARS-CoV-2 infection: A prospective cohort study

A prospective cohort study was conducted for adults diagnosed with COVID-19. Convalescent blood was obtained at 4, 6, and 11 months after SARS-CoV-2 infection. The seropositivity of anti-spike antibody was maintained in all patients (100%) until 11 months after COVID-19. Neutralizing antibody levels...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2022-02
Main Authors: Noh, Ji Yun, Yang, Jeong-Sun, Hwang, Soon Young, Hyun, Hakjun, Seong, Hye, Yoon, Jin Gu, Yoon, Soo-Young, Cheong, Hee Jin, Kim, Woo Joo, Park, Woo-Jung, Kim, Jun-Won, Lee, Joo-Yeon, Song, Joon Young
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A prospective cohort study was conducted for adults diagnosed with COVID-19. Convalescent blood was obtained at 4, 6, and 11 months after SARS-CoV-2 infection. The seropositivity of anti-spike antibody was maintained in all patients (100%) until 11 months after COVID-19. Neutralizing antibody levels against the wild-type SARS-CoV-2 gradually decreased but remained positive in more than 50% of patients 11 months after diagnosis: 98.5% (67/68) at 4 months, 86.8% (46/53) at 6 months, and 58.8% (40/68). However, cross-neutralizing activity against the Beta and Delta variants was attenuated 2.53-fold and 2.93-fold, respectively, compared to the wild-type strain.
ISSN:1537-6613